RS BioTherapeutics develops life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation.
RS BioTherapeutics’ Reg CF raise launched on April 29, 2024. Learn more about this pathbreaking company and the investment opportunity at: https://www.startengine.com/offering/rs-biotherapeutics
By Jossey PLLC, www.thecrowdfundinglawyers.com
Jossey PLLC performed paid legal work for this capital raise
